A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused ...
Several tumor features were linked with a higher chance of pCR: no or low ER levels, low or no progesterone receptor levels, ...
Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo ...
For children with high-risk B-cell acute lymphoblastic leukemia (ALL), replacing part of their intensive chemotherapy with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results